COMPARE · Data as of August 27, 2026
CPRT vs DLB
Verdict: Side-by-side breakdown using the Bull Rankings model. CPRT scored 54.0, DLB scored 64.7 — DLB leads.
Compare another set
CPRT
Copart, Inc.
54
$32.76 · $30.3B
fundamentals as of
Score gap
10.7
DLB leads
DLB
Dolby Laboratories, Inc.
64.7
$63.58 · $6.0B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestCPRT20.3x
- Fastest growthDLB+5.9%
- Strongest balance sheetCPRT0.01
- Highest qualityCPRT90 / 100
- Largest discount to fair valueDLB-8%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
CPRT
stronger →← stronger
DLB
90
Qualityreturns · margins · balance sheet
73
36
Growthrevenue & earnings expansion
65
49
Valuevaluation vs sector peers
57
DLB is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
CPRT
DLB
$1.3bC+
FCF
$345mC
+1.0%C
Rev
+5.9%C+
0.01A
D/E
0.02A
20.3xB+
P/E
27.1xB
4.00D
PEG
1.29B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
CPRT
DLB
46% above
Price vs fair valuelower is cheaper
8% below
~14%/yr
Growth the price implies10-yr FCF · lower = less priced in
~3%/yr
-34%
1-yr DCF upside
+5%
-31%
5-yr DCF upside
+9%
-28%
10-yr DCF upside
+16%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
CPRT
Why this score
- Buying back stock
- Durable high returns
DLB
Why this score
- Raising its dividend
The companies
CPRTCopart, Inc.
Why now
Specialty Business Services · market cap $30.3b. Down 35% from 52-week high of $50.11 — deep drawdown territory. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $40.20 (implying +23% upside).
Moat
Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Down 35% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
DLBDolby Laboratories, Inc.
Why now
Specialty Business Services · market cap $6.0b. 14% off the 52-week high of $73.78. 3 sell-side analysts publish a mean 1-yr target of $79.00 (implying +24% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 152% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where CPRT and DLB diverge
On the headline score the gap is 10.7 points in favor of DLB. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthCPRT 35.9 · DLB 65.0DLB +29.1
- QualityCPRT 89.7 · DLB 73.4CPRT +16.3
- ValueCPRT 48.8 · DLB 56.7DLB +7.9
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.